Placebo News and Research

RSS

Estrogen only hormone replacement not so risky after 50’s: Study

According to a new study hormone therapy may not be as risky for elder women as earlier thought. This comes from the Women's Health Initiative, a federally funded trial that tracked thousands of women taking hormones or placebo pills for years. The WHI looked at women who have had hysterectomies or have had their uterus removed and thus can take estrogen unaccompanied by another hormone, progestin. It found that a heightened risk of stroke from taking estrogen faded with time, while a reduced risk of breast cancer held steady.

5 Apr 2011

Individual’s response to alcohol can predict future drinking behavior

For some people, alcohol is a social lubricant. For others, it's an unpleasant downer. New research shows that a person's response to alcohol can predict their future drinking behavior, including their frequency of binge drinking and the risk of developing an alcohol-use disorder.

5 Apr 2011

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Curis, Inc., a drug development company seeking to develop next generation targeted small molecule drug candidates for cancer treatment, today announced the presentation of interim Phase II clinical data on Hedgehog pathway inhibitor vismodegib in patients with basal cell nevus syndrome, which is also commonly referred to as Gorlin syndrome.

5 Apr 2011

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Idera Pharmaceuticals, Inc. today announced the presentation of data from its multiple-dose Phase 1 clinical trial of IMO-3100 in healthy subjects.

5 Apr 2011

Current Alzheimer Research publishes ExonHit's EHT 0202 Phase IIa results

ExonHit Therapeutics today announced the publication of Phase IIa results for EHT 0202, its lead candidate for the treatment of Alzheimer's disease, in the journal Current Alzheimer Research.

5 Apr 2011

Cardioxyl's CXL-1020 preclinical data against heart failure presented at ACC meeting

Cardioxyl Pharmaceuticals, Inc. announced today that it is presenting two abstracts from studies of its lead clinical candidate, CXL-1020, at the American College of Cardiology's 60th Annual Scientific Session & Expo in New Orleans, Louisiana.

5 Apr 2011

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Avanir Pharmaceuticals, Inc. today announced that it has filed an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) to begin a large Phase II clinical trial of AVP-923, an investigational drug for the treatment of central neuropathic pain in patients with multiple sclerosis (MS). The FDA has acknowledged receipt of the submission and the company expects that the IND filing will be subject to standard 30-day review.

4 Apr 2011

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

Abbott and Enanta Pharmaceuticals today announced 12-week results from a Phase 2 study of ABT-450/r, an investigational, oral protease inhibitor being developed for the treatment of hepatitis C infection.

4 Apr 2011

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

Bristol-Myers Squibb Company today announced results from a Phase II clinical trial in which treatment with the investigational direct-acting antiviral BMS-790052, an NS5A replication complex inhibitor, in combination with PEG-Interferon alfa and ribavirin, achieved sustained virologic response 12 weeks post-treatment in up to 92% of treatment-naïve patients chronically infected with hepatitis C genotype 1.

4 Apr 2011

Positive results from GDC-0449 Phase II data against basal cell nevus syndrome

A new hedgehog pathway inhibitor demonstrated efficacy in preventing and treating basal cell cancer among patients with basal cell nevus syndrome, a rare inheritable disease, according to Phase II data presented at the AACR 102nd Annual Meeting 2011, held April 2-6.

4 Apr 2011

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

New data presented today at the International Liver CongressTM 2011, the 46th Annual Meeting of the European Association for the Study of the Liver, in Berlin, highlighted the efficacy of Boehringer Ingelheim's once-daily oral protease inhibitor BI 201335, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus infection. Genotype-1 HCV is the most challenging genotype of HCV to treat.

2 Apr 2011

Thalidomide provides new hope for patients with difficult to treat liver cancer

Thalidomide has shown potential to be used as the first adjuvant therapy for hepatocellular carcinoma, according to data presented at the International Liver Congress 2011.

2 Apr 2011

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Boehringer Ingelheim today announced a preview of the study designs for the pivotal Phase 3 clinical trials evaluating BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype to treat.

2 Apr 2011

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

New data presented today at the 46th Annual Meeting of the European Association for the Study of the Liver demonstrate the antiviral activity of Boehringer Ingelheim's once-daily oral protease inhibitor, BI 201335, in both treatment-naive and -experienced patients with chronic genotype-1 hepatitis C virus, the most challenging genotype of HCV to treat.

1 Apr 2011

APEX-PD Phase III clinical study data to be presented at American Academy of Neurology Conference

Impax Pharmaceuticals, the branded products division of Impax Laboratories, Inc., today announced that IPX066 APEX-PD Phase III clinical study data will be presented in a Late Breaker Session at the 63rd annual meeting of the American Academy of Neurology Conference in Honolulu, Hawaii, held from April 9 to April 16.

1 Apr 2011

Obeticholic Acid safe and effective against Primary Biliary Cirrhosis

Results from an international study presented today at the International Liver Congress have shown Obeticholic Acid (OCA) is a safe and effective treatment in patients suffering from Primary Biliary Cirrhosis (PBC) as demonstrated by substantial decreases in the levels of alkaline phosphatase (AP) enzyme in the blood, a key marker for PBC.

1 Apr 2011

Novartis, Intercell to initiate Pseudomonas vaccine trial in ventilated ICU patients

Today Intercell AG announced that it has agreed with Novartis to advance Intercell's investigational Pseudomonas aeruginosa vaccine into a confirmatory clinical efficacy trial in ventilated ICU patients.

1 Apr 2011

Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

Medivir AB, the emerging research-based specialty pharmaceutical company focused on infectious diseases, announces that their partner, Tibotec has presented the results of a planned Week 24 interim analysis of the phase 2b ASPIRE study for TMC435 in treatment experienced hepatitis C patients in a late-breaker session at the 46th Annual meeting of the European Association for the Study of the Liver, Berlin, Germany.

1 Apr 2011

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

CorMedix Inc., a pharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of cardiorenal disease, today announced its interim analysis and clinical update for CRMD001.

1 Apr 2011

New data confirms antiviral activity of fluvastatin in patients with HCV

New data presented today at the International Liver CongressTM confirm the antiviral activity of fluvastatin -- commonly used as a cholesterol-lowering treatment -- in patients with chronic hepatitis C.

1 Apr 2011

Placebo News and Research

Estrogen only hormone replacement not so risky after 50’s: Study

Individual’s response to alcohol can predict future drinking behavior

Curis presents vismodegib Phase II data in basal cell nevus syndrome at AACR meeting

Idera presents IMO-3100 Phase 1 trial data in autoimmune diseases at Keystone Symposia

Current Alzheimer Research publishes ExonHit's EHT 0202 Phase IIa results

Cardioxyl's CXL-1020 preclinical data against heart failure presented at ACC meeting

Avanir files IND for NUEDEXTA/AVP-923 Phase II clinical trial for central neuropathic pain in MS patients

Abbott and Enanta's ABT-450/r Phase 2 study results against HCV presented at EASL meeting

BMY announces BMS-790052 plus PEG-Interferon alfa and RBV Phase II trial results against HCV

Positive results from GDC-0449 Phase II data against basal cell nevus syndrome

Boehringer Ingelheim's BI 201335 new data against HCV highlighted at EASL meeting

Thalidomide provides new hope for patients with difficult to treat liver cancer

Boehringer Ingelheim advances into Phase 3 clinical trial of BI 201335

Results of Boehringer Ingelheim's BI 201335 study presented at Annual Meeting of EASL

APEX-PD Phase III clinical study data to be presented at American Academy of Neurology Conference

Obeticholic Acid safe and effective against Primary Biliary Cirrhosis

Novartis, Intercell to initiate Pseudomonas vaccine trial in ventilated ICU patients

Tibotec presents TMC435 phase 2b study interim results against HCV at EASL meeting

CorMedix reports encouraging interim results from CRMD001 phase II study in Contrast Induced Acute Kidney Injury

New data confirms antiviral activity of fluvastatin in patients with HCV

Industry Focus eBook - Cell & Gene Therapy (1st Edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News